Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

This study aimed to determine whether nonalcoholic fatty liver disease (NAFLD) is an independent risk factor for CVD and to identify the most useful NAFLD diagnostic tool for predicting CVD. Data from a total of 23,376 Korean adults without established CVD were analyzed. Cardiovascular risk was calculated using the Framingham Risk Score (FRS) 2008. The presence of NAFLD was defined as moderate-to-severe fatty liver disease diagnosed by ultrasonography. Scores for fatty liver were calculated using four NAFLD scoring systems (Fatty Liver Index, FLI; Hepatic Steatosis Index, HSI; Simple NAFLD Score, SNS; Comprehensive NAFLD Score, CNS), and were compared and analyzed according to cardiovascular risk group. Using the FRS, 67.4% of participants were considered to be at low risk of CVD, 21.5% at intermediate risk, and 11.1% at high risk. As the risk of CVD increased, both the prevalence of NAFLD and the score from each NAFLD scoring system increased significantly ( < 0.001). In the unadjusted analysis, the CNS had the strongest association with high CVD risk; in the adjusted analysis, the FLI score was most strongly associated with high CVD risk. Fatty liver is an important independent risk factor for CVD. Therefore, the available NAFLD scoring systems could be utilized to predict CVD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303122PMC
http://dx.doi.org/10.3390/healthcare9070899DOI Listing

Publication Analysis

Top Keywords

fatty liver
24
risk
12
cardiovascular risk
12
liver disease
12
scoring systems
12
nafld scoring
12
nafld score
12
nafld
9
cvd
9
nonalcoholic fatty
8

Similar Publications

The treatment of metabolic dysfunction-associated steatotic liver disease involves physical activity, weight loss, and management of comorbidities (diabetes, hypertension, dyslipidemia). In 2024, the American Food and Drug Administration provisionally approved resmetirom for metabolic dysfunction-associated steatohepatitis. Other promising molecules are being evaluated (glucagon-like peptide 1 receptor agonists, fibroblast growth factor 21 agonist).

View Article and Find Full Text PDF

Background: Water hardness, which refers to the level of dissolved calcium and magnesium salts, is of significant public health concern due to its potential impact on health. The association between water hardness and digestive diseases remains underexplored, with limited evidence from small-scale clinical studies. Given the rising prevalence of digestive disorders worldwide, large-scale cohort studies are needed to address this gap in the literature.

View Article and Find Full Text PDF

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a major contributor to systemic metabolic dysfunction and is increasingly recognized as a risk enhancer for both cardiovascular disease (CVD) and chronic kidney disease (CKD). This review explores the complex interconnections between MASLD, CVD, and CKD, with emphasis on shared pathophysiological mechanisms and the clinical implications for risk assessment and management. We describe the crosstalk among the liver, heart, and kidneys, focusing on insulin resistance, chronic inflammation, and progressive fibrosis as key mediators.

View Article and Find Full Text PDF

Background: (Benth.) Baker is a perennial shrub endemic to the Tibetan Plateau. Its seeds are traditional Tibetan medicine for treating jaundice, hepatitis, purulent tonsillitis, diphtheria, and parasitosis.

View Article and Find Full Text PDF

Background: Vitamin D insufficiency is increasingly recognized as a significant and underlying contributor to a wide range of musculoskeletal disorders, particularly in gastrointestinal (GI) and endocrine health. The study aims to determine the clinical relationship between vitamin D status and the severity of GI symptoms, while also assessing the impact of related endocrine disturbances.

Methods: A cross-sectional study was conducted involving 120 adult patients with GI problems, including constipation, bloating, irritable bowel syndrome (IBS), and dyspepsia in a tertiary care hospital over a six-month duration.

View Article and Find Full Text PDF